{"podcast":{"title":"The ONS Podcast","slug":"the-ons-podcast-1126448","podcast_index_feed_id":1126448,"rss_url":"https://onsvoice.libsyn.com/rss","website_url":"http://onsvoice.libsyn.com/website","image_url":"https://static.libsyn.com/p/assets/a/4/9/b/a49b61aa05d5c66416c3140a3186d450/PodcastRevampFinal.jpg","author":"Oncology Nursing Society","episode_count":423,"summary":"Where ONS Voices Talk Cancer Join oncology nurses on the Oncology Nursing Society's award-winning podcast as they sit down to discuss the topics important to nursing practice and treating patients with cancer. ISSN 2998-2308","last_synced_at":"2026-06-19T16:20:50.610700+00:00","page_url":"https://stenobird.com/podcast/the-ons-podcast-1126448"},"episode":{"title":"Episode 403: Pharmacology 101: Checkpoint Inhibitors","slug":"episode-403-pharmacology-101-checkpoint-inhibitors","published_at":"2026-02-20T08:00:00+00:00","page_url":"https://stenobird.com/podcast/the-ons-podcast-1126448/episode-403-pharmacology-101-checkpoint-inhibitors","show_page_url":"https://stenobird.com/podcast/the-ons-podcast-1126448","url":"https://onsvoice.libsyn.com/episode-403-pharmacology-101-checkpoint-inhibitors","audio_url":"https://traffic.libsyn.com/secure/onsvoice/403_-_Checkpoint_Inhibitors_mixdown.mp3?dest-id=557038","summary":"\"Because the premise of immune checkpoint blockade centers around elevating the immune function, we should always take a great deal of caution around those patients who have high immune risks. Those include patients with autoimmune disorders. That's one of our biggest questions that we ask, usually every consult that we're seeing with solid tumor. 'Do you have any history of autoimmune disorders? Tell me a little bit more about it. Is it being treated? What are your symptoms like?' And then also patients who have undergone organ transplants. Now, interestingly, this does include stem cell transplants,\" Kelsey Finch, PharmD, BCOP, oncology pharmacist practitioner at Columbus Regional Health in Indiana, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS ® , manager of oncology nursing practice at ONS, during a conversation about checkpoint inhibitors. Music Credit: \" Fireflies and Stardust \" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 20, 2027. Kelsey Finch has disclosed a speakers bureau relationship with AstraZeneca. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to checkpoint inhibitors in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD . ONS Podcast ™ episodes: Pharmacology 101 series Episode 273: Updates in Chemotherapy and Immunotherapy Episode 174: Administer Pembrolizumab Immunotherapy With Confidence Episode 139: How CAR and…","meta_description":"\"Because the premise of immune checkpoint blockade centers around elevating the immune function, we should always take a great deal of caution around thos…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2059,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-ons-podcast-1126448/episodes/episode-403-pharmacology-101-checkpoint-inhibitors/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-ons-podcast-1126448/episode-403-pharmacology-101-checkpoint-inhibitors.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}